Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marla Dubinsky

Showing results (51-60 of 151) with videos related to

Pageof 16
Sort By:
Diseases of the Colon and Rectum|December 19, 2007
Family history and serology predict Crohn's disease after ileal pouch-anal anastomosis for ulcerative colitisGil Y Melmed, Phillip R Fleshner, Ovunc Bardakcioglu, et al.
Alimentary Pharmacology & Therapeutics|December 4, 2018
The effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in paediatric patients with Crohn's disease: a post hoc analysisJeffrey S Hyams, Marla Dubinsky, Joel Rosh, et al.
The American Journal of Gastroenterology|November 26, 2025
Bowel Urgency in Crohn's Disease: Bridging the Gap Between Patients and Healthcare ProvidersMarla Dubinsky, Alison Potts Bleakman, Stephan Vavricka, et al.
Human Genetics|January 16, 2021
Meta-analysis of sample-level dbGaP data reveals novel shared genetic link between body height and Crohn's diseaseAntonio Di Narzo, Itziar Frades, Heidi M Crane, et al.
Digestive Diseases and Sciences|October 24, 2019
Correction to: Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel DiseasesAndres J Yarur, Alexandra Bruss, Snehal Naik, et al.
Journal of Pediatric Gastroenterology and Nutrition|January 31, 2025
Ustekinumab is safe and effective in pediatric patients with Crohn's diseaseElana B Mitchel, Michael T Dolinger, Brad Constant, et al.
Digestive Diseases and Sciences|March 6, 2019
Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel DiseasesAndres J Yarur, Alexandra Bruss, Snehal Naik, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 24, 2022
Combination Therapy With Immunomodulators Improves the Pharmacokinetics of Infliximab But Not Vedolizumab or UstekinumabAndres J Yarur, Dermot McGovern, Maria T Abreu, et al.
Advances in Therapy|March 14, 2023
Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn's DiseaseEdward V Loftus, Jenny Griffith, Ezequiel Neimark, et al.
Journal of Cutaneous Medicine and Surgery|March 17, 2015
Pyoderma Gangrenosum among Patients with Inflammatory Bowel Disease: A Descriptive Cohort StudyAdam V Weizman, Brian Huang, Stephan Targan, et al.
Pageof 16

Showing results (51-60 of 151) with videos related to

Sort By:
Pageof 16
Diseases of the Colon and Rectum|December 19, 2007
Family history and serology predict Crohn's disease after ileal pouch-anal anastomosis for ulcerative colitisGil Y Melmed, Phillip R Fleshner, Ovunc Bardakcioglu, et al.
Alimentary Pharmacology & Therapeutics|December 4, 2018
The effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in paediatric patients with Crohn's disease: a post hoc analysisJeffrey S Hyams, Marla Dubinsky, Joel Rosh, et al.
The American Journal of Gastroenterology|November 26, 2025
Bowel Urgency in Crohn's Disease: Bridging the Gap Between Patients and Healthcare ProvidersMarla Dubinsky, Alison Potts Bleakman, Stephan Vavricka, et al.
Human Genetics|January 16, 2021
Meta-analysis of sample-level dbGaP data reveals novel shared genetic link between body height and Crohn's diseaseAntonio Di Narzo, Itziar Frades, Heidi M Crane, et al.
Digestive Diseases and Sciences|October 24, 2019
Correction to: Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel DiseasesAndres J Yarur, Alexandra Bruss, Snehal Naik, et al.
Journal of Pediatric Gastroenterology and Nutrition|January 31, 2025
Ustekinumab is safe and effective in pediatric patients with Crohn's diseaseElana B Mitchel, Michael T Dolinger, Brad Constant, et al.
Digestive Diseases and Sciences|March 6, 2019
Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel DiseasesAndres J Yarur, Alexandra Bruss, Snehal Naik, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 24, 2022
Combination Therapy With Immunomodulators Improves the Pharmacokinetics of Infliximab But Not Vedolizumab or UstekinumabAndres J Yarur, Dermot McGovern, Maria T Abreu, et al.
Advances in Therapy|March 14, 2023
Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn's DiseaseEdward V Loftus, Jenny Griffith, Ezequiel Neimark, et al.
Journal of Cutaneous Medicine and Surgery|March 17, 2015
Pyoderma Gangrenosum among Patients with Inflammatory Bowel Disease: A Descriptive Cohort StudyAdam V Weizman, Brian Huang, Stephan Targan, et al.
Pageof 16